MAPK-interacting kinases inhibition by eFT508 overcomes chemoresistance in preclinical model of osteosarcoma
Human & Experimental Toxicology · 2023
DOI: 10.1177/09603271231158047 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human & Experimental Toxicology, 2023. Verfasst von Bin Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, Xiangyang No.1 People's Hospital, 36841Hubei University of Medicine, Xiangyang, China. Hauptthemen laut MEDLINE: Bone Neoplasms, Drug Resistance, Neoplasm, Osteosarcoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Hubei University of Medicine.
Abstract (Originalsprache)
The MAPK-interacting kinases 1 and 2 (MNK1/2) have generated increasing interest as therapeutic targets for many cancers with little known in osteosarcoma. This study evaluated the efficacy of eFT508, a highly selective inhibitor of MNK1/2, as single drug alone and in combination with paclitaxel in preclinical models of osteosarcoma. EFT508 is active against multiple osteosarcoma cell lines via inhibiting growth, survival and migration. It also demonstrates anti-osteosarcoma selectivity with much less toxicity on normal osteoblastic than osteosarcoma cells. Consistent with in vitro findings, eFT508 at non-toxic dose significantly arrested tumor growth in mice throughout the whole duration of treatment. Mechanistically, eEFT508 is highly effective in blocking eIF4E phosphorylation and eIF4E-mediated protein translation. Combination index shows that eFT508 and paclitaxel is synergistic in osteosarcoma cells. Our findings highlight the therapeutic value of MNK1/2 inhibition and suggest eFT508 as a promising candidate for the treatment of osteosarcoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedics, Xiangyang No.1 People's Hospital, 36841Hubei University of Medicine, Xiangyang, China.
ORCID-Profile: Junhu Duan
Förderung
- Hubei University of Medicine
Zitieren
APA
Huang, B., Jin, P., Yi, K., & Duan, J. (2023). MAPK-interacting kinases inhibition by eFT508 overcomes chemoresistance in preclinical model of osteosarcoma. Human & Experimental Toxicology. https://doi.org/10.1177/09603271231158047
Vancouver
Huang B, Jin P, Yi K, Duan J. MAPK-interacting kinases inhibition by eFT508 overcomes chemoresistance in preclinical model of osteosarcoma. Human & Experimental Toxicology. 2023. doi:10.1177/09603271231158047
BibTeX
@article{Huang2023,
author = {Huang, Bin and Jin, Peicheng and Yi, Kaijun and Duan, Junhu},
title = {MAPK-interacting kinases inhibition by eFT508 overcomes chemoresistance in preclinical model of osteosarcoma},
journal = {Human & Experimental Toxicology},
year = {2023},
doi = {10.1177/09603271231158047}
}
EUVIMED